Lixte Biotech Hlds (LIXT)

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $BYND $LIXT $NMAX $NNDM $GME

$LIXT Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology. “LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion,” said Geordan Pursglove, Chairman and Chief Executive Officer. “We remain focused on advancing LB-100 in high-need cancer indications, while pursuing acquisitions of complementary oncology assets that could enhance our pipeline, accelerate development and create durable value for patients and shareholders.”

$LIXT fighting disease, AITX fighting inefficiency — this momentum shows what operational execution really means.

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $SBFM $LIXT $GEVO $BULL $GME

$LIXT scam , bleeding everyday until 0.50

$LIXT Cmon now. Don't be bearish

$LIXT looks like a scam , 0.50 soon

$LIXT I like 5.95+ 25+% gains coming from this level. Buy lower gains go up.

$LIXT going to 0.50 slowly everyday LOL

$LIXT Biotech with clinical catalyst. High short interest. Volatility expansion expected. Pure binary event risk.

$LIXT coming soon

$LIXT So we should only be expecting some Ovarian Cancer updates sometime in the Fourth Quarter. Colorectal on Hold for Adverse affects and Sarcoma Trial at the Netherlands put on the Back Burner due to market size???? Makes me feel less Confident.

$LIXT When combined with chemotherapy, radiation, or immunotherapy, LB-100 is showing potential to strip away resistance and reveal tumors that were once untouchable. Found some early Concerns here: MSS Colorectal Cancer (Roche Partnership): Conducted in collaboration with Roche, which is providing atezolizumab and full trial funding, at the Netherlands Cancer Institute. Enrollment is under a temporary voluntary safety pause following early adverse events. Soft-Tissue Sarcoma: Phase 1 completed successfully with no toxicity concerns. Phase 2 has been discontinued to prioritize immunotherapy combination programs with higher commercial potential.

$LIXT Said more directly, LB-100 drives tumors into a death spiral, pushing them into lethal overdrive until their own survival systems collapse. In other words, it becomes cancer's most lethal enemy. By inhibiting PP2A, LB-100 disrupts cancer's ability to repair itself, floods cells with stress signals, and even generates neoantigens that expose tumors to the immune system. In effect, it turns cold, invisible cancers into hot targets for immunotherapy.

$LIXT Earlier this month, the company put the focus squarely on its lead compound, LB-100. It is the only clinical-stage inhibitor of protein phosphatase 2A (PP2A), a cellular enzyme that cancers hijack to survive treatment. So why does PP2A matter? Think of it as the circuit breaker in cancer's wiring system. When therapies cause DNA damage or stress inside a tumor cell, PP2A shuts things down, giving the cell a chance to recover. Most treatments try to kill cancer directly. LB-100 takes a different approach: it disables the breaker, stripping cancer of its emergency escape route and leaving cells defenseless against therapy.

$LIXT I think it’s going to bounce off the support level here and have a Green Day tomorrow with a few pretty decent spikes. In here at this price and we will see what happens tomorrow.

$LIXT $GNLX $VVOS $PBM my 4 bio horseman .. each one still can 10X from current levels

$LIXT did ceo pursglove go back to $BYOC dedicated or is he still working both companies? As of yesterday disappeared from yahoo finance profile lixt. Two days ago was showing there. Cfo stazzone still shows in both profiles. Pursglove shows as ceo byoc profile.

Spartan Capital Securities and B2i Digital are pleased to announce that Lixte Biotechnology Holdings, Inc. (Nasdaq: $LIXT) will be a presenting company at the upcoming Spartan Capital Securities, LLC Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Investors can register to attend: https://www.meetmax.com/sched/event_125183/investor_reg_new.html?attendee_role_id=SPARTAN_INVESTOR_ATT. Event details and registration are available at https://b2idigital.com/spartan-capital-investor-conference-2025. Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors. In recent years, the field of cancer treatment has undergone remarkable advancement with the introduction of immunotherapy. This approach has revolutionized the landscape of cancer care. Both chemotherapy, and immunotherapy are treatment modalities that offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients. Our lead molecule LB-100 has shown remarkable synergy with chemotherapy and immunotherapy in a range of pre-clinical models. The company is led by CEO Geordan Pursglove, an accomplished executive with 10+ years in M&A and capital markets; CSO Bastiaan (Bas) van der Baan, a biotechnology executive with 20+ years in precision oncology; CFO Peter Stazzone, a seasoned finance professional and CPA with 25 years of expertise; and supported by a Scientific Advisory Committee including Prof. Rene Bernards, Stephen Forman MD, and Yun Yen MD PhD FACP. B2i Digital is working closely with the Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Learn more about Lixte Biotechnology Holdings, Inc. at https://ir.lixte.com/

$LIXT LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future

$LIXT They certainly get my vote for best small biotech PR of all time after today's!